
Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
Dec 10, 2019
Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for ...
Read More



A helping hand in treatment of CRC
Feb 27, 2019
Patients suffering from Colorectal Cancer (CRC) usually gets affected with distant organ metastases spreading the tumor to other parts of the body. Patients with unresectab...
Read More
Neuroendocrine tumors (NETs): The complex group of tumors
Sep 10, 2018
Neuroendocrine tumors (NETs) consists of complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body....
Read More
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker
Sep 6, 2018
Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular ...
Read More
Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd
Aug 24, 2018
Hepato Cellular Carcinoma (HCC) Not all deadly battles are lost. Some are won too.It is without the slightest doubt that the ones won are the typical examples of smart mana...
Read More
AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal
Aug 23, 2018
AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million thro...
Read More

Fatty Acid Amide Hydrolase (FAAH) Inhibitors – Pipeline Insights, 2015 – A DelveInsight’s Report
Sep 21, 2015
Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis of bioactive fatty acid ethanolam...
Read More